ID: ALA606435

Max Phase: Preclinical

Molecular Formula: C12H16N6O4

Molecular Weight: 308.30

Molecule Type: Small molecule

Representations

Canonical SMILES:  CN(C)C(=O)[C@H]1OC(n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O

Standard InChI:  InChI=1S/C12H16N6O4/c1-17(2)11(21)8-6(19)7(20)12(22-8)18-4-16-5-9(13)14-3-15-10(5)18/h3-4,6-8,12,19-20H,1-2H3,(H2,13,14,15)/t6-,7+,8-,12?/m0/s1

Standard InChI Key:  IATMAQXWZNAXLV-QQIVLSGASA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 308.30

Molecular Weight (Monoisotopic): 308.1233

AlogP: -1.88

#Rotatable Bonds: 2

Polar Surface Area: 139.62

Molecular Species: NEUTRAL

HBA: 9

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 10

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 12.40

CX Basic pKa: 3.94

CX LogP: -2.13

CX LogD: -2.13

Aromatic Rings: 2

Heavy Atoms: 22

QED Weighted: 0.59

Np Likeness Score: 0.53

References

1. Matsuda A, Kosaki H, Saitoh Y, Yoshimura Y, Minakawa N, Nakata H..  (1998)  Nucleosides and nucleotides. 177. 9-(6,7-dideoxy-beta-D-allo-hept-5- ynofuranosyl)adenine: a selective and potent ligand for P3 purinoceptor-like protein.,  41  (15): [PMID:9667957] [10.1021/jm9802822]

2. Prasad RN, Bariana DS, Fung A, Savic M, Tietje K, Stein HH, Brondyk H, Egan RS..  (1980)  Modification of the 5' position of purine nucleosides. 2. Synthesis and some cardiovascular properties of adenosine-5'-(N-substituted)carboxamides.,  23  (3): [PMID:7365748] [10.1021/jm00177a021]

Source

Source(1):

• Scientific Literature